Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy for lupus nephritis (LN). This follows the clinical trial hold placed by ...

Introduction: Lupus nephritis (LN ... In addition, the patients in the nephritis group had a significantly greater SLEDAI score. Statistically significant greater doses of steroids were administered ...

The Lupus Foundation of America (LFA) is dedicated to reducing time to diagnosis, and one program that directly tackles this is Be Fierce. Take Control. The campaign targets young Hispanic/Latina and ...

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab ... and similar to other ...

Kidney inflammation caused by SLE is referred to as lupus nephritis (LN), and it is estimated that between 40% and 50% of all SLE patients will develop LN that requires treatment over the course ...

Correspondence to Dr Chi Chiu Mok, Department of Medicine, Tuen Mun Hospital, Hong Kong; ccmok2005{at}yahoo.com Objective To compare the efficacy of tacrolimus (TAC) and mycophenolate mofetil (MMF) ...

Most of the time you will have a team of physicians and therapists who will help you control the symptoms of your disease as well as its limitations ... with some primary care physicians acting as the ...

Four patients experienced alleviation of symptoms and reduced their daily prednisone dosages ... Three patients also had concurrent lupus nephritis (LN), 1 each with class IV, class I, and class IV+V.

from the time they first notice their lupus symptoms. Diagnostic delays significantly increase the likelihood for excessive organ damage and poorer prognosis over the long-term. "The Lupus ...

July 10, 2024 — Scientists have discovered a molecular defect that promotes the pathologic immune response in systemic lupus erythematosus (known as lupus) and show that reversing this defect ...

The community came together to celebrate and honor Javari Fannin, an 18-year-old lupus survivor, who will be recognized as the 2024 Survivor Recipient at the upcoming Night of Hope Lupus Gala.